



FINAL STUDY REPORT

PROTOCOL TITLE

Virucidal Efficacy of a Disinfectant for Use on Inanimate Environmental Surfaces

Virus: Human Immunodeficiency Virus type 1

DATA REQUIREMENT

U.S. EPA 40 CFR Part 158,
"Data Requirements for Registration"
Pesticide Assessment Guidelines - Subdivision G, 91-2(f)

PRODUCT IDENTITY

Accel TB
Lot # 13423 and Lot # 13501

PROTOCOL NUMBER

VIR07122104.HIV

PROJECT NUMBER

A02661

AUTHOR

Mary J. Miller, M.T.
Study Director

STUDY COMPLETION DATE

February 10, 2005

PERFORMING LABORATORY

ATS Labs
1285 Corporate Center Drive, Suite 110
Eagan, MN 55121

SPONSOR

Virox Technologies, Inc.
2815 Bristol Circle, Unit 4
Oakville, Ontario L6H 6X5
CANADA

Project No. A02661
Protocol Number: VIR07122104.HIV

Virox Technologies, Inc.
Page 2 of 14



STATEMENT OF NO DATA CONFIDENTIALITY CLAIMS

No claim of confidentiality is made for any information contained in this study on the basis of its falling within the scope of FIFRA Section 10 (d) (1) (A), (B), or (C).

Company: Virox Technologies, Inc.

Company Agent: _____

_____ Title

_____ Signature

Date: _____

Project No. A02661
Protocol Number: VIR07122104.HIV

Virox Technologies, Inc.
Page 3 of 14



GOOD LABORATORY PRACTICE STATEMENT

The study referenced in this report was conducted in compliance with U.S. Environmental Protection Agency Good Laboratory Practice (GLP) regulations set forth in 40 CFR part 160.

The procedures not performed by or under the direction of ATS Labs are exempt from this Good Laboratory Practice statement and include: characterization and stability of the compound(s).

Submitter: _____

Date: _____

Sponsor: _____

Date: _____

Study Director: Mary J. Miller
Mary J. Miller, M.T.

Date: 2-10-05

Project No. A02661
 Protocol Number: VIR07122104.HIV

Virox Technologies, Inc.
 Page 4 of 14



QUALITY ASSURANCE UNIT SUMMARY

Study: Virucidal Efficacy of a Disinfectant for Use on Inanimate Environmental Surfaces

The objective of the Quality Assurance Unit is to monitor the conduct and reporting of nonclinical laboratory studies. This study has been performed under Good Laboratory Practice regulations (40 CFR Part 160) and in accordance to standard operating procedures and a standard protocol. The Quality Assurance Unit maintains copies of study protocols and standard operating procedures and has inspected this study on the date(s) listed below. Studies are inspected at time intervals to assure the integrity of the study.

Phase Inspected	Date	Study Director	Management
Critical Phase	January 26, 2005	January 26, 2005	February 10, 2005
Final Report	February 10, 2005	February 10, 2005	

The findings of these inspections have been reported to management and the Study Director.

Quality Assurance Auditor: Crenda Sims Date: 2/10/05

Project No. A02661
Protocol Number: VIR07122104.HIV

Virox Technologies, Inc.
Page 5 of 14



TABLE OF CONTENTS

Title Page..... 1

Statement of No Data Confidentiality Claims..... 2

Good Laboratory Practice Statement 3

Quality Assurance Unit Summary 4

Table of Contents..... 5

Study Personnel..... 6

General Study Information 7

Test Substance Identity..... 7

Study Dates 7

Objective 7

Summary of Results 8

Test System 8

Methods 9

Protocol Changes..... 10

Data Analysis 11

Study Retention..... 11

References..... 11

Study Results..... 12

Study Conclusion 12

Table 1: Virus Control and Test Substance Assay Results..... 13

Table 2: Cytotoxicity Control Results..... 13

Table 3: Neutralization Control Results 14

Project No. A02661
Protocol Number: VIR07122104.HIV

Virox Technologies, Inc.
Page 6 of 14



STUDY PERSONNEL

STUDY DIRECTOR: Mary J. Miller, M.T.

Professional Personnel Involved:

Karen M. Ramm, B.A. - Technical Director
Katherine A. Paulson, M.L.T. - Research Assistant II

Project No. A02661
Protocol Number: VIR07122104.HIV

Virox Technologies, Inc.
Page 7 of 14



STUDY REPORT

GENERAL STUDY INFORMATION

Study Title: Virucidal Efficacy of a Disinfectant for Use on Inanimate Environmental Surfaces
Project Number: A02661
Protocol Number: VIR07122104.HIV
Sponsor: Virox Technologies, Inc.
2815 Bristol Circle, Unit 4
Oakville, Ontario L6H 6X5 CANADA
Testing Facility: ATS Labs
1285 Corporate Center Drive, Suite 110
Eagan, MN 55121

TEST SUBSTANCE IDENTITY

Test Substance Name: Accel TB
Batch/Lot(s): Lot # 13423 and Lot # 13501

Test Substance Characterization

Test substance characterization as to content, stability, solubility, storage, etc., is the responsibility of the Sponsor.

STUDY DATES

Date Sample Received: December 27, 2004
Study Initiation Date: January 10, 2005
Experimental Start Date: January 26, 2005
Experimental End Date: February 3, 2005
Study Completion Date: February 10, 2005

OBJECTIVE

The objective of this study was to evaluate the virucidal efficacy of a disinfectant against Human Immunodeficiency Virus type 1 according to test criteria and methods approved by the United States Environmental Protection Agency (U.S. EPA) for registration of a product as a virucide.

Project No. A02661
Protocol Number: VIR07122104.HIV

Virox Technologies, Inc.
Page 8 of 14



SUMMARY OF RESULTS

Test Substance: Accel TB, Lot # 13423 and Lot # 13501

Dilution: Ready to use (RTU)

Virus: Human Immunodeficiency Virus type 1, Strain HTLV-III_B

Exposure Time: Five minutes

Exposure Temperature: Room temperature (22.0°C)

Organic Soil Load: 5% fetal bovine serum

Efficacy Result: Two lots of Accel TB (Lot # 13423 and Lot # 13501) met the test criteria specified in the study protocol. The results indicate **complete inactivation** of Human Immunodeficiency Virus type 1 under these test conditions as required by the U.S. EPA for claims of virucidal activity.

TEST SYSTEM

1. Virus
The HTLV-III_B strain of Human Immunodeficiency Virus type 1 (HIV-1) used for this study was obtained from Advanced Biotechnologies, Inc., Columbia, MD. The stock virus was stored at ≤-70°C until the day of use. On the day of use an aliquot of stock virus (Advanced Biotechnologies, Inc. Lot 2K0014A) was removed, thawed and refrigerated until use in the assay. The stock virus culture was adjusted to contain 5% fetal bovine serum as the organic soil load. The stock virus tested demonstrated cytopathic effects (CPE) typical of HIV on MT-2 cells.
2. Test Cell Cultures
MT-2 cells (human CD4+ lymphocytes) were originally obtained from the National Cancer Institute, Frederick, MD. Cultures were grown and propagated in-house and used in suspension in disposable tissue culture labware. On the day of testing, cells were observed as having proper cell integrity and therefore, were acceptable for use in this study.
3. Test Medium
The test medium used in this study was RPMI-1640 supplemented with 15% (v/v) heat-inactivated fetal bovine serum (FBS). The medium was also supplemented with 2.0 mM L-glutamine and 50 µg/mL gentamicin.

Project No. A02661

Virox Technologies, Inc.

Protocol Number: VIR07122104.HIV

Page 9 of 14



The following table lists the test and control groups, the dilutions assayed, and the number of cultures used. See text for a more detailed explanation.

NUMBER OF DILUTIONS AND CULTURES FOR VIRUCIDAL EFFICACY STUDY			
Test or Control Group	Dilutions Assayed (log₁₀)	Cultures per dilution	Total Cultures
Cell Control	N/A	4	4/group
Dried Virus Control (Group A)	-1,-2,-3,-4,-5,-6,-7	4	28
Sample lot #1 + virus (Group B)	-1,-2,-3,-4,-5,-6,-7	4	28
Sample lot #2 + virus (Group B)	-1,-2,-3,-4,-5,-6,-7	4	28
Cytotoxicity of lot #1 (Group C)	-1,-2,-3,-4,-5,-6,-7	4	28
Cytotoxicity of lot #2 (Group C)	-1,-2,-3,-4,-5,-6,-7	4	28
Non-Virucidal level - lot #1 (Group D)	-1,-2,-3,-4,-5,-6,-7	4	28
Non-Virucidal level - lot #2 (Group D)	-1,-2,-3,-4,-5,-6,-7	4	28

METHODS

1. Preparation of Test Substance

Two lots of Accel TB (Lot # 13423 and Lot # 13501) were used, undiluted, as received from the Sponsor. The test substance was in solution as determined by visual observation.

2. Preparation of Virus Films

Films of virus were prepared by spreading 0.2 mL of virus inoculum uniformly over the bottoms of three separate 100 x 15mm sterile glass petri dishes. The virus films were air-dried at room temperature (25.0°C) until visibly dry (20 minutes) and then incubated at 36-38°C for an additional 30 minutes to increase the level of dryness.

3. Sephadex Gel Filtration

To reduce the cytotoxic level of the virus-test substance mixture prior to assay of virus and/or to reduce the virucidal level of the test substance, virus was separated from the test substance by filtration through Sephadex gel. Columns of Sephadex LH-20-100 were equilibrated with phosphate buffered saline containing 1% albumin, centrifuged for three minutes to clear the void volume, loaded with approximately 2.0 mL of virus-test substance mixture and immediately passed through the column utilizing the syringe plunger.

Project No. A02661

Virox Technologies, Inc.

Protocol Number: VIR07122104.HIV

Page 10 of 14



4. Treatment of Virus Films with Test Substance (GROUP B, TABLE 1)
For each lot of test substance separate dried virus films were exposed to 2.0 mL of the use dilution for five minutes at room temperature (22.0°C). Following the exposure time, the plates were scraped with a cell scraper to resuspend the contents of the plate and the virus-disinfectant mixture was immediately passed through a Sephadex column utilizing the syringe plunger in order to detoxify the mixture. The filtrate (10^{-1} dilution) was then titered by 10-fold serial dilution and assayed for infectivity.
5. Treatment of Virus Control Film (GROUP A, TABLE 1)
A virus film was prepared as previously described (paragraph 2). The control film was exposed to 2.0 mL of test medium for the same amount of time as the test film was exposed to the test substance. The virus was then scraped and passed through a Sephadex column in the same manner as the test virus and the filtrate (10^{-1} dilution) was then titered by 10-fold serial dilution and assayed for infectivity.
6. Cytotoxicity Assay (GROUP C, TABLE 2)
A 2.0 mL aliquot of the use dilution of each lot of the test substance was filtered through a Sephadex column and the filtrate was diluted serially in medium and inoculated into MT-2 cell cultures. Cytotoxicity of the MT-2 cell cultures was scored at the same time as the virus-test substance and virus control cultures.
7. Assay of Non-Virucidal Level of Test Substance (GROUP D, TABLE 3)
Each dilution of the Sephadex-filtered test substance (test substance control for cytotoxicity assay) was mixed with an aliquot of low titer stock virus, and the resulting mixtures of dilutions were assayed for infectivity in order to determine the dilution(s) of test substance at which virucidal activity, if any, was retained. Dilutions that showed virucidal activity were not considered in determining the reduction in infectivity by the test substance.
8. Infectivity Assays
The MT-2 cell line, which exhibits CPE in the presence of HIV-1, was used as the indicator cell line in the infectivity assays. Cells in multiwell culture dishes were inoculated in quadruplicate with 0.2 mL of the dilutions prepared from test and control groups. Uninfected indicator cell cultures (cell controls) were inoculated with test medium alone. Cultures were incubated at 36-38°C in a humidified atmosphere of 5-7% CO₂ in sterile disposable cell culture labware. The cultures were scored periodically for eight days for the absence or presence of CPE, cytotoxicity, and for viability.
9. Statistical Methods: N/A

PROTOCOL CHANGES

Protocol Amendments:

No protocol amendments were required for this study.

Protocol Deviations:

No protocol deviations occurred during this study.

Project No. A02661
 Protocol Number: VIR07122104.HIV

Virox Technologies, Inc.
 Page 11 of 14



DATA ANALYSIS

Calculation of Titers

Viral and cytotoxicity titers are expressed as $-\log_{10}$ of the 50 percent titration endpoint for infectivity (TCID₅₀) or cytotoxicity (TCD₅₀), respectively, as calculated by the method of Spearman Karber.

$$-\text{Log of 1st dilution inoculated} - \left[\left(\left(\frac{\text{Sum of \% mortality at each dilution}}{100} \right) - 0.5 \right) \times (\text{logarithm of dilution}) \right]$$

Calculation of Log Reduction

Dried Virus Control TCID₅₀ – Test Substance TCID₅₀ = Log Reduction

STUDY RETENTION

Record Retention

All of the original raw data developed exclusively for this study shall be archived at ATS Labs, 1285 Corporate Center Drive, Suite 110, Eagan, MN 55121. These original data include, but are not limited to, the following:

1. All handwritten raw data for control and test substances including, but not limited to, notebooks, data forms and calculations.
2. Any protocol amendments/deviation notifications.
3. All measured data used in formulating the final report.
4. Memoranda, specifications, and other study specific correspondence relating to interpretation and evaluation of data, other than those documents contained in the final study report.
5. Original signed protocol.
6. Certified copy of the final study report.
7. Study-specific SOP deviations made during the study.

Test Substance Retention

The test substance will be discarded following study completion per Sponsor approved protocol. It is the responsibility of the Sponsor to retain a sample of the test material.

REFERENCES

1. Annual Book of ASTM Standards 2000, Section 11 Water and Environmental Technology Volume 11.05 Biological Effects and Environmental Fate: Biotechnology; Pesticides, E1053-97.
2. U.S. Environmental Protection Agency Pesticide Assessment Guidelines, Subdivision G: Product Performance, 91-2(f), November 1982.
3. U.S. Environmental Protection Agency, Registration Division, Office of Pesticide Programs, DIS/TSS-7, November 12, 1981.
4. Diagnostic Procedures for Viral, Rickettsial, and Chlamydial Infections. Schmidt, N.J. and Emmons, R.W. editors. Sixth edition, 1989. p. 18-20.
5. Blackwell, J.H., and J.H.S. Chen. 1970. Effects of various germicidal chemicals on HEP-2 cell culture and Herpes simplex virus. J. AOAC 53:1229-1236.
6. Techniques in HIV Research, A. Aidovini and B. Walker, 1990.

Project No. A02661
Protocol Number: VIR07122104.HIV

Virox Technologies, Inc.
Page 12 of 14



STUDY RESULTS

Results of tests with two lots of Accel TB (Lot # 13423 and Lot # 13501), ready to use, exposed to HIV-1 virus in the presence of a 5% fetal bovine serum soil load at room temperature (22.0°C) for five minutes are shown in Tables 1-3. All cell controls were negative for test virus infectivity. The titer of the dried virus control was 5.5 log₁₀. Following exposure, test virus infectivity was not detected in the virus-test substance mixture for either lot at any dilution tested (≤ 1.5 log₁₀). Test substance cytotoxicity was observed in both lots at 1.5 log₁₀. The neutralization control (non-virucidal level of the test substance) indicates that the test substance was neutralized at ≤ 1.5 log₁₀ for both lots. Taking the cytotoxicity and neutralization control results into consideration, the reduction in viral titer was ≥ 4.0 log₁₀ for both lots.

STUDY CONCLUSION

Under the conditions of this investigation, in the presence of a 5% fetal bovine serum soil load, Accel TB (Lot # 13423 and Lot # 13501), ready to use, demonstrated complete inactivation of Human Immunodeficiency Virus type 1 following a five minute exposure time at room temperature (22.0°C) as required by the U.S. EPA for virucidal label claims.

In the opinion of the Study Director, there were no circumstances that may have adversely affected the quality or integrity of the data.

The use of the ATS Labs name, logo or any other representation of ATS Labs without the written approval of ATS Labs is prohibited. In addition, ATS Labs may not be referred to in any form of promotional materials, press releases, advertising or similar materials (whether by print, broadcast, communication or electronic means) without the express written permission of ATS Labs.

Project No. A02661

Virox Technologies, Inc.

Protocol Number: VIR07122104.HIV

Page 13 of 14

**TABLE 1: Virus Control and Test Substance Assay Results****Effects of Accel TB Following a Five Minute Exposure to HIV-1 Dried on an Inanimate Surface**

Dilution	Dried Virus Control (GROUP A)	HIV-1 + Lot # 13423 (GROUP B)	HIV-1 + Lot # 13501 (GROUP B)
Cell Control	0 0 0 0	0 0 0 0	0 0 0 0
10 ⁻¹	+ + + +	T T T T	T T T T
10 ⁻²	+ + + +	0 0 0 0	0 0 0 0
10 ⁻³	+ + + +	0 0 0 0	0 0 0 0
10 ⁻⁴	+ + + +	0 0 0 0	0 0 0 0
10 ⁻⁵	+ + + +	0 0 0 0	0 0 0 0
10 ⁻⁶	0 0 0 0	0 0 0 0	0 0 0 0
10 ⁻⁷	0 0 0 0	0 0 0 0	0 0 0 0
TCID ₅₀ /0.2 mL	10 ^{5.5}	≤10 ^{1.5}	≤10 ^{1.5}

TABLE 2: Cytotoxicity Control Results**Cytotoxicity of Accel TB on MT-2 Cell Cultures**

Dilution	Cytotoxicity Control Lot # 13423 (GROUP C)	Cytotoxicity Control Lot # 13501 (GROUP C)
Cell Control	0 0 0 0	0 0 0 0
10 ⁻¹	T T T T	T T T T
10 ⁻²	0 0 0 0	0 0 0 0
10 ⁻³	0 0 0 0	0 0 0 0
10 ⁻⁴	0 0 0 0	0 0 0 0
10 ⁻⁵	0 0 0 0	0 0 0 0
10 ⁻⁶	0 0 0 0	0 0 0 0
10 ⁻⁷	0 0 0 0	0 0 0 0
TCD ₅₀ /0.2 mL	10 ^{1.5}	10 ^{1.5}

(+) = Positive for the presence of test virus

(0) = No test virus recovered and/or no cytotoxicity present

(T) = Cytotoxicity present

Project No. A02661

Virox Technologies, Inc.

Protocol Number: VIR07122104.HIV

Page 14 of 14



TABLE 3: Neutralization Control Results
Non-Virucidal Level of Test Substance (Neutralization Control)

Dilution	Test Virus + Cytotoxicity Control Lot # 13423 (GROUP D)	Test Virus + Cytotoxicity Control Lot # 13501 (GROUP D)
Cell Control	0 0 0 0	0 0 0 0
10 ⁻¹	T T T T	T T T T
10 ⁻²	+ + + +	+ + + +
10 ⁻³	+ + + +	+ + + +
10 ⁻⁴	+ + + +	+ + + +
10 ⁻⁵	+ + + +	+ + + +
10 ⁻⁶	+ + + +	+ + + +
10 ⁻⁷	+ + + +	+ + + +

(+) = Positive for the presence of test virus after low titer stock virus added (neutralization control)

(0) = No test virus recovered and/or no cytotoxicity present

(T) = Cytotoxicity present

Results of the non-virucidal level control indicate that the test substance was neutralized at a TCID₅₀ of ≤1.5 log₁₀ for both lots.